A folate receptor-α-specific ligand that targets cancer tissue and not sites of inflammation

Journal of Nuclear Medicine

Volumn 53, Issue 7, 2012, Pages 1127-1134

  Vaitilingam, Balasubramanian ^a   Chelvam, Venkatesh ^a   Kularatne, Sumith A ^a   Poh, Scott ^a   Ayala Lopez, Wilfredo ^a   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Folate receptor alpha specific ligand; Optical and radioimaging of tumors; Tumor targeted therapy

Indexed keywords

DIMETHYL TETRAHYDROFOLATE TC 99M; ETARFOLATIDE TC 99M; FOLATE RECEPTOR 1; FOLATE RECEPTOR 2; FOLIC ACID; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TETRAHYDROFOLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CANCER CELL; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERLIPOPROTEINEMIA TYPE 3; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; IN VIVO STUDY; MACROPHAGE; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOCYTE; MOUSE; MUSCLE INJURY; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCINTIGRAPHY; ULCERATIVE COLITIS;

ANIMALS; ARTHRITIS; ATHEROSCLEROSIS; CELL LINE, TUMOR; CHELATING AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; FLOW CYTOMETRY; FOLATE RECEPTOR 1; HUMANS; INFLAMMATION; KB CELLS; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MUSCLE, SKELETAL; NEOPLASMS; ORGANOTECHNETIUM COMPOUNDS; PATCH-CLAMP TECHNIQUES; RADIOPHARMACEUTICALS; RATS; SUBSTRATE SPECIFICITY; TECHNETIUM; TETRAHYDROFOLATES; TISSUE DISTRIBUTION;

EID: 84863451148     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.099390     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. Faststats. Available at: www.cdc. gov/nchs/fastats/lcod.htm. Accessed May 25, 2012.
2. Jemal A, Siegel R, Ward E. Cancer Statistics 2008. CA Cancer J Clin. 2008;58: 71-96.
3. Deane NG, Manning HC, Foutch AC, et al. Targeted imaging of colonic tumors in smad3-/- mice discriminates cancer and inflammation. Mol Cancer Res. 2007;5:341-349.
4. van Waarde A, Elsinga HP. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des. 2008;14:3326-3339.
5. de Visser EK, Jonkers J. Towards understanding the role of cancer associated inflammation in chemoresistance. Curr Pharm Des. 2009;15:1844-1853.
6. Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst. 1998;15:587-627.
7. Lu Y, Low PS. Folate mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002;54:675-693.
8. Lu Y, Sega E, Low PS. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J Cancer. 2005;116:710-719.
9. 67Ga-deferoxaminefolate, a potential radiopharmaceutical for tumor imaging. Bioconjug Chem. 1996; 7:56-62.
10. Mathias CJ, Low PS. Indium-111-DTPA-folate as a potential folate-receptortargeted radiopharmaceutical. J Nucl Med. 1998;39:1579-1585.
11. 99mTc-based radiopharmaceutical. Bioconjug Chem. 2002; 13:1200-1210.
12. 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate receptor targeted PET radiopharmaceuticals. Nucl Med Biol. 2003;30:725-731.
13. 111In-DTPA-folate as a receptor targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med. 2003;44:700-707.
14. Low PS, Kularatne SK. Folate targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009;13:256-262.
15. Low PS, Antony CA. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev. 2004;56:1055-1058.
16. Turk MJ, Breur GJ, Widmer WR. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 2002;46:1947-1955.
17. Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev. 2004;56:1205-1217.
18. Paulos CM, Varghese B, Widmer WR, Breur GJ, Vlashi E, Low PS. Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res Ther. 2006;8:R77.
19. Ayala-López W, Xia W, Varghese B, Low PS. Imaging of atherosclerosis in apoliprotein E knockout mice: targeting of a folate-conjugated radiopharmaceutical to activated macrophages. J Nucl Med. 2010;51:768-774.
20. Wang X, Shen F, Freisheim JH, Gentry LE, Ratnam M. Differential stereo specificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem Pharmacol. 1992;44:1898-1901.
21. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004; 56:1067-1084.
22. Maziarz KM, Monaco HL, Shen F, Ratnam M. Complete mapping of divergent aminoacids responsible for differential ligand binding of folate receptors alpha and beta. J Biol Chem. 1999;274:11086-11091.
23. Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood. 2009;113:438-446.
24. He W, Wang H, Hartmann LC, Cheng JC, Low PS. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci USA. 2007;104:11760-11765.
25. 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts. Nucl Med Biol. 1999;26:23-25.
26. Yamashita T, Kawashima S, Ozaki M, Yokoyama M. Propagermanium reduces atherosclerosis in apolipoprotein E knockout mice via inhibition of macrophage infiltration. Arterioscler Thromb Vasc Biol. 2002;22:969-974.
27. Yan Z, Choi S, Liu S, Zhang M, Williams RS. Highly coordinated gene regulation in mouse skeletal muscle regeneration. J Biol Chem. 2003;278:8826-8836.
28. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-546.
29. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol. 2005;288:R345-R353.
30. Ognjanovic S, Hainaut P. Inflammation in carcinogenesis. Compr Toxicol. 2010;401-415.
31. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid based receptor targeting for imaging and therapy of cancer and inflammatory disease. Acc Chem Res. 2008;41:120-129.
32. Dose-Schwarz J, Tiling R, Avril-Sassen S, et al. Assessment of residual tumor by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. Br J Cancer. 2010; 102:35-41.
33. Dantal J, Soulillou J-P. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005;352:1371-1373.